BioSpace News Archive

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2019.

Accelmed Partners, a U.S. based private equity firm focused on investments in commercial stage healthtech companies, announced today that Evan Norton, long-term veteran at Abbott Laboratories, has joined as General Partner.

Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) and Tarveda Therapeutics, Inc. (“Tarveda”), a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction.

Kura Oncology Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib

Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020

Algernon Pharmaceuticals Inc. is pleased to announce that Dr. Martin Kolb, a leading global scientific expert and clinician in the area of idiopathic pulmonary fibrosis, has joined the Algernon Medical and Scientific Advisory Board.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors.

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced Friedreich’s ataxia (FA) as the therapeutic indication for the company’s first neurology development program.

Consonance Capital Partners, a leading healthcare-focused private equity fund, announced today that it signed a definitive agreement to sell Enclara Healthcare (“Enclara”), along with management, to Humana Inc. (NYSE: HUM or “Humana”).